M. Gaga (Athens, Greece), P. Kirkham (Wolverhampton , United Kingdom)
Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial
M. Patel, J. Pilcher, D. Shaw, M. Weatherall, R. Beasley (Wellington, New Zealand; Nottingham, United Kingdom)
|   |
Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety
H. A. M. Kerstjens, E. Bleecker, E. Meltzer, T. Casale, E. Pizzichini, O. Schmidt, M. Engel, L. J. Bour, C. B. Verkleij, P. M. Moroni-Zentgraf, E. D. Bateman (Groningen, Alkmaar, Netherlands; Winston-Salem, San Diego, Omaha, United States Of America; Santa Catarina, Brazil; Koblenz, Ingelheim am Rhein, Biberach an der Riss, Germany; Cape Town, South Africa)
| |
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV)
L. Weisfeld, G. Gopalan, Y. Shu, B. Baconnet, T. Shah (Miami, Frazer, United States Of America; Maisons Alfort, France)
| |
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients
A. Sharma, J. Hohlfeld, P. Cornelissen, J. van Noord, E. Derom, L. Towse, V. Peterkin, B. Disse (Biberach, Hannover, Ingelheim, Germany; Alkmaar, Heerlen, Netherlands; Ghent, Belgium; Bracknell, United Kingdom)
|  |
Chronic kidney disease as effect modifier in the association between the use of tiotropium respimat and mortality
K. Verhamme, N. van Blijderveen, S. Romio, B. Stricker, G. Brusselle, M. Sturkenboom (Rotterdam, Netherlands; Ghent, Belgium; Milan, Italy)
| |
Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD
H. Watz, K. M. Beeh, H. Magnussen, L. de Theresa, D. Jarreta, C. Caracta, E. Garcia Gil (Grosshansdorf, Wiesbaden, Germany; Alicante, Barcelona, Spain; Jersey City, United States Of America)
| |
Glycopyrronium does not affect QT interval in healthy subjects: A randomized, 3-period cross-over, placebo- and positive-controlled study
A. Drollmann, R. Sechaud, P. Pal, H. Hara, S. Uziel-Fusi, P. Winkle (Basel, Switzerland; Hyderabad, India; East Hanover, Anaheim, United States Of America)
| |
The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies
P. Lange, J. L. Aumann, E. Derom, A. Hamilton, K. Tetzlaff, N. Ting, J. A. van Noord (Hvidovre, Denmark; Hasselt, Ghent, Belgium; Burlington, Canada; Biberach, Germany; Ridgefield, United States Of America; Heerlen, Netherlands)
| |